Document:

Exhibit 10.149

                                                                       EXHIBIT C

NEITHER  THESE  SECURITIES  NOR THE  SECURITIES  ISSUABLE UPON EXERCISE OF THESE
SECURITIES HAVE BEEN  REGISTERED WITH THE SECURITIES AND EXCHANGE  COMMISSION OR
THE  SECURITIES  COMMISSION  OF ANY STATE IN  RELIANCE  UPON AN  EXEMPTION  FROM
REGISTRATION  UNDER THE  SECURITIES  ACT OF 1933,  AS AMENDED  (THE  "SECURITIES
ACT"),  AND,  ACCORDINGLY,  MAY NOT BE OFFERED  OR SOLD  EXCEPT  PURSUANT  TO AN
EFFECTIVE  REGISTRATION  STATEMENT  UNDER THE  SECURITIES  ACT OR PURSUANT TO AN
AVAILABLE  EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE  REGISTRATION
REQUIREMENTS  OF THE  SECURITIES  ACT AND IN ACCORDANCE  WITH  APPLICABLE  STATE
SECURITIES  LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO
SUCH  EFFECT,  THE  SUBSTANCE  OF WHICH SHALL BE  REASONABLY  ACCEPTABLE  TO THE
COMPANY.  THESE  SECURITIES AND THE  SECURITIES  ISSUABLE UPON EXERCISE OF THESE
SECURITIES MAY BE PLEDGED IN CONNECTION  WITH A BONA FIDE MARGIN ACCOUNT SECURED
BY SUCH SECURITIES.

                         CALYPTE BIOMEDICAL CORPORATION

                                     WARRANT

Warrant No. [  ]                              Original Issue Date:  July 9, 2004

      Calypte Biomedical  Corporation,  a Delaware  corporation (the "COMPANY"),
hereby  certifies that, for value received,  [ ] or its registered  assigns (the
"HOLDER"), is entitled to purchase from the Company up to a total of [ ]1 shares
of Common Stock (each such share,  a "WARRANT  SHARE" and all such  shares,  the
"WARRANT SHARES"), at any time and from time to time from and after the Original
Issue Date and through and including July 9, 2009 (the "EXPIRATION  DATE"),  and
subject to the following terms and conditions:

      1.  Definitions.  As used in this Warrant,  the following terms shall have
the respective  definitions set forth in this Section 1. Capitalized  terms that
are used and not  defined  in this  Warrant  that are  defined  in the  Purchase
Agreement (as defined below) shall have the respective  definitions set forth in
the Purchase Agreement.

      "BUSINESS DAY" means any day except Saturday, Sunday and any day that is a
federal  legal  holiday  in  the  United  States  or  a  day  on  which  banking
institutions in the State of New York are authorized or required by law or other
government action to close.

--------------
1     A number of shares as equals 70% of the Shares  issuable to such  Investor
      at Closing under the Purchase Agreement.

<PAGE>

      "COMMON  STOCK" means the common stock of the Company,  par value $.03 per
share,  and any  securities  into  which  such  common  stock may  hereafter  be
reclassified.

      "EXERCISE  PRICE" means $0.50,  subject to adjustment  in accordance  with
Section 9.

      "ORIGINAL ISSUE DATE" means the Original Issue Date first set forth on the
first page of this Warrant.

      "NEW YORK COURTS" means the state and federal  courts  sitting in the City
of New York, Borough of Manhattan.

      "PURCHASE  AGREEMENT" means the Securities Purchase Agreement,  dated July
9, 2004, to which the Company and the original Holders are parties.

      "TRADING  DAY"  means (i) a day on which the  Common  Stock is traded on a
Trading Market (other than the OTC Bulletin Board),  or (ii) if the Common Stock
is not listed on a Trading Market (other than the OTC Bulletin  Board), a day on
which the Common Stock is traded in the over-the-counter  market, as reported by
the OTC  Bulletin  Board,  or (iii) if the  Common  Stock is not  quoted  on any
Trading   Market,   a  day  on  which  the   Common   Stock  is  quoted  in  the
over-the-counter   market  as  reported  by  the   National   Quotation   Bureau
Incorporated (or any similar  organization or agency succeeding to its functions
of reporting prices);  provided,  that in the event that the Common Stock is not
listed or quoted as set forth in (i),  (ii) and (iii)  hereof,  then Trading Day
shall mean a Business Day.

      2.  Registration of Warrant.  The Company shall register this Warrant upon
records  to be  maintained  by  the  Company  for  that  purpose  (the  "WARRANT
REGISTER"),  in the name of the  record  Holder  hereof  from time to time.  The
Company may deem and treat the registered Holder of this Warrant as the absolute
owner hereof for the purpose of any exercise  hereof or any  distribution to the
Holder, and for all other purposes, absent actual notice to the contrary.

      3.  Registration of Transfers.  The Company shall register the transfer of
any portion of this  Warrant in the Warrant  Register,  upon  surrender  of this
Warrant,  with the Form of Assignment attached hereto duly completed and signed,
to the Company at its address  specified  herein.  Upon any such registration or
transfer,  a new Warrant to purchase Common Stock, in substantially  the form of
this Warrant (any such new Warrant, a "NEW Warrant"),  evidencing the portion of
this Warrant so transferred  shall be issued to the transferee and a New Warrant
evidencing  the remaining  portion of this Warrant not so  transferred,  if any,
shall be issued to the transferring Holder. The acceptance of the New Warrant by
the transferee  thereof shall be deemed the acceptance by such transferee of all
of the rights and obligations of a holder of a Warrant.

      4. Exercise and Duration of Warrants. This Warrant shall be exercisable by
the registered Holder at any time and from time to time on or after the Original
Issue Date through and including  the  Expiration  Date. At 6:30 p.m.,  New York
City time on the  Expiration  Date,  the portion of this  Warrant not  exercised
prior thereto shall be and become void and of no value. The Company may not call
or redeem any portion of this Warrant  without the prior written  consent of the
affected Holder.

                                       2
<PAGE>

      5. Delivery of Warrant Shares.

            (a) To effect exercises hereunder,  the Holder shall not be required
to  physically  surrender  this  Warrant  unless the  aggregate  Warrant  Shares
represented  by this Warrant is being  exercised.  Upon delivery of the Exercise
Notice (in the form attached  hereto) to the Company (with the attached  Warrant
Shares Exercise Log) at its address for notice set forth herein and upon payment
of the Exercise Price multiplied by the number of Warrant Shares that the Holder
intends to purchase hereunder, the Company shall promptly (but in no event later
than three  Trading Days after the Date of Exercise (as defined  herein))  issue
and deliver to the Holder,  a certificate  for the Warrant Shares  issuable upon
such exercise, which, unless otherwise required by the Purchase Agreement, shall
be free of restrictive  legends.  The Company shall,  upon request of the Holder
and subsequent to the date on which a registration statement covering the resale
of the Warrant Shares has been declared effective by the Securities and Exchange
Commission,  use its reasonable best efforts to deliver Warrant Shares hereunder
electronically  through the Depository Trust Corporation or another  established
clearing corporation performing similar functions, if available, provided, that,
the Company may,  but will not be required to change its  transfer  agent if its
current transfer agent cannot deliver Warrant Shares electronically  through the
Depository Trust  Corporation.  A "DATE OF EXERCISE" means the date on which the
Holder shall have  delivered to the Company:  (i) the Exercise  Notice (with the
Warrant  Exercise Log attached to it),  appropriately  completed and duly signed
and (ii) if such Holder is not utilizing the cashless  exercise  provisions  set
forth in this Warrant,  payment of the Exercise  Price for the number of Warrant
Shares so indicated by the Holder to be purchased.

            (b) If by the third Trading Day after a Date of Exercise the Company
fails to deliver the required  number of Warrant  Shares in the manner  required
pursuant to Section  5(a),  then the Holder will have the right to rescind  such
exercise.

            (c) If by the third Trading Day after a Date of Exercise the Company
fails to deliver the required  number of Warrant  Shares in the manner  required
pursuant to Section  5(a),  and if after such third Trading Day and prior to the
receipt  of such  Warrant  Shares,  the  Holder  purchases  (in an  open  market
transaction or otherwise) shares of Common Stock to deliver in satisfaction of a
sale by the Holder of the Warrant Shares which the Holder anticipated  receiving
upon such exercise (a  "BUY-IN"),  then the Company shall (1) pay in cash to the
Holder the amount by which (x) the  Holder's  total  purchase  price  (including
brokerage  commissions,  if any) for the  shares  of Common  Stock so  purchased
exceeds (y) the amount  obtained by multiplying (A) the number of Warrant Shares
that the Company was  required to deliver to the Holder in  connection  with the
exercise at issue by (B) the  closing bid price of the Common  Stock at the time
of the obligation giving rise to such purchase  obligation and (2) at the option
of the Holder, either reinstate the portion of the Warrant and equivalent number
of  Warrant  Shares for which such  exercise  was not  honored or deliver to the
Holder the number of shares of Common  Stock that would have been issued had the
Company timely  complied with its exercise and delivery  obligations  hereunder.
The Holder  shall  provide the Company  written  notice  indicating  the amounts
payable to the Holder in respect of the Buy-In.

                                       3
<PAGE>

            (d) The Company's obligations to issue and deliver Warrant Shares in
accordance with the terms hereof are absolute and unconditional, irrespective of
any action or inaction by the Holder to enforce the same,  any waiver or consent
with respect to any provision  hereof,  the recovery of any judgment against any
Person  or  any  action  to  enforce  the  same,  or any  setoff,  counterclaim,
recoupment,  limitation or  termination,  or any breach or alleged breach by the
Holder or any other Person of any  obligation to the Company or any violation or
alleged violation of law by the Holder or any other Person,  and irrespective of
any other  circumstance  which  might  otherwise  limit such  obligation  of the
Company to the Holder in connection with the issuance of Warrant Shares. Nothing
herein shall limit a Holder's right to pursue any other remedies available to it
hereunder,  at law or in  equity  including,  without  limitation,  a decree  of
specific  performance  and/or  injunctive  relief with respect to the  Company's
failure to timely deliver certificates representing Warrant Shares upon exercise
of the Warrant as required pursuant to the terms hereof.

      6. Charges,  Taxes and Expenses.  Issuance and delivery of Warrant  Shares
upon exercise of this Warrant shall be made without charge to the Holder for any
issue or transfer tax,  withholding tax,  transfer agent fee or other incidental
tax or expense in respect of the  issuance  of such  certificates,  all of which
taxes and expenses  shall be paid by the Company;  provided,  however,  that the
Company  shall not be required to pay any tax which may be payable in respect of
any transfer involved in the registration of any certificates for Warrant Shares
or  Warrants  in a name  other  than that of the  Holder.  The  Holder  shall be
responsible for all other tax liability that may arise as a result of holding or
transferring this Warrant or receiving Warrant Shares upon exercise hereof.

      7. Replacement of Warrant.  If this Warrant is mutilated,  lost, stolen or
destroyed,  the  Company  shall  issue or cause to be  issued  in  exchange  and
substitution for and upon  cancellation  hereof,  or in lieu of and substitution
for this Warrant,  a New Warrant,  but only upon receipt of evidence  reasonably
satisfactory to the Company of such loss, theft or destruction and customary and
reasonable  indemnity  (which shall not include a surety  bond),  if  requested.
Applicants  for a New Warrant  under such  circumstances  shall also comply with
such other  reasonable  regulations and procedures and pay such other reasonable
third-party costs as the Company may prescribe. If a New Warrant is requested as
a result of a mutilation  of this  Warrant,  then the Holder shall  deliver such
mutilated  Warrant to the  Company as a  condition  precedent  to the  Company's
obligation to issue the New Warrant.

      8.  Reservation of Warrant Shares.  The Company  covenants that it will at
all times reserve and keep  available out of the aggregate of its authorized but
unissued  and  otherwise  unreserved  Common  Stock,  solely for the  purpose of
enabling  it to issue  Warrant  Shares upon  exercise of this  Warrant as herein
provided,  the number of Warrant Shares which are then issuable and  deliverable
upon the exercise of this entire  Warrant,  free from  preemptive  rights or any
other  contingent  purchase rights of Persons other than the Holder (taking into
account the  adjustments and  restrictions of Section 9). The Company  covenants
that all Warrant Shares so issuable and deliverable shall, upon issuance and the
payment of the applicable Exercise Price in accordance with the terms hereof, be
duly and validly authorized, issued and fully paid and nonassessable.

      9. Certain  Adjustments.  The Exercise  Price and number of Warrant Shares
issuable upon  exercise of this Warrant are subject to  adjustment  from time to
time as set forth in this Section 9.

                                       4
<PAGE>

            (a) Stock  Dividends and Splits.  If the Company,  at any time while
this Warrant is  outstanding,  (i) pays a stock  dividend on its Common Stock or
otherwise  makes a distribution on any class of capital stock that is payable in
shares of Common Stock, (ii) subdivides  outstanding shares of Common Stock into
a larger number of shares, or (iii) combines  outstanding shares of Common Stock
into a smaller number of shares, then in each such case the Exercise Price shall
be multiplied by a fraction of which the numerator shall be the number of shares
of Common  Stock  outstanding  immediately  before  such  event and of which the
denominator   shall  be  the  number  of  shares  of  Common  Stock  outstanding
immediately after such event. Any adjustment made pursuant to clause (i) of this
paragraph  shall  become  effective  immediately  after the record  date for the
determination of stockholders entitled to receive such dividend or distribution,
and any  adjustment  pursuant  to clause (ii) or (iii) of this  paragraph  shall
become  effective  immediately  after the effective date of such  subdivision or
combination.

            (b) Fundamental Transactions.  If, at any time while this Warrant is
outstanding,  (1) the Company effects any merger or consolidation of the Company
with  or into  another  Person,  (2)  the  Company  effects  any  sale of all or
substantially all of its assets in one or a series of related transactions,  (3)
any tender offer or exchange offer (whether by the Company or another Person) is
completed  pursuant to which  holders of Common Stock are permitted to tender or
exchange their shares for other securities, cash or property, or (4) the Company
effects  any  reclassification  of the  Common  Stock  or any  compulsory  share
exchange  pursuant to which the Common Stock is  effectively  converted  into or
exchanged  for  other  securities,  cash  or  property  (in  any  such  case,  a
"FUNDAMENTAL  TRANSACTION"),  then the Holder shall have the right thereafter to
receive,  upon exercise of this Warrant, the same amount and kind of securities,
cash or property as it would have been  entitled to receive upon the  occurrence
of such  Fundamental  Transaction  if it had  been,  immediately  prior  to such
Fundamental  Transaction,  the  holder of the  number  of  Warrant  Shares  then
issuable upon exercise in full of this Warrant (the "ALTERNATE  CONSIDERATION").
For purposes of any such exercise, the determination of the Exercise Price shall
be appropriately adjusted to apply to such Alternate  Consideration based on the
amount of  Alternate  Consideration  issuable  in respect of one share of Common
Stock in such  Fundamental  Transaction,  and the Company  shall  apportion  the
Exercise  Price  among  the  Alternate  Consideration  in  a  reasonable  manner
reflecting  the relative  value of any  different  components  of the  Alternate
Consideration.  If  holders  of Common  Stock  are  given  any  choice as to the
securities,  cash or property to be received in a Fundamental Transaction,  then
the Holder shall be given the same choice as to the Alternate  Consideration  it
receives  upon  any  exercise  of  this  Warrant   following  such   Fundamental
Transaction. At the Holder's option and request, any successor to the Company or
surviving entity in such Fundamental  Transaction shall, either (1) issue to the
Holder a new warrant  substantially  in the form of this Warrant and  consistent
with the foregoing  provisions and evidencing the Holder's right to purchase the
Alternate  Consideration for the aggregate Exercise Price upon exercise thereof,
or (2)  purchase the Warrant  from the Holder for a purchase  price,  payable in
cash within five Trading Days after such request (or, if later, on the effective
date of the  Fundamental  Transaction),  equal to the Black Scholes value of the
remaining  unexercised portion of this Warrant on the date of such request.  The
terms of any agreement  pursuant to which a Fundamental  Transaction is effected
shall include terms  requiring any such successor or surviving  entity to comply
with the  provisions of this paragraph (c) and insuring that the Warrant (or any
such  replacement  security)  will be  similarly  adjusted  upon any  subsequent
transaction analogous to a Fundamental Transaction.

                                       5
<PAGE>

            (c) Subsequent Equity Sales.

                  (i) If the Company or any  subsidiary  thereof,  as applicable
with  respect to Common  Stock  Equivalents,  at any time while this  Warrant is
outstanding,  shall issue any securities of the Company or any Subsidiary  which
entitle  the  holder  thereof  to acquire  Common  Stock at any time,  including
without limitation,  any debt, preferred stock, rights, options, warrants or any
other instrument that is at any time  convertible  into or exchangeable  for, or
otherwise  entitles the holder thereof to receive,  Common Stock or Common Stock
Equivalents  entitling any Person to acquire shares of Common Stock,  at a price
per share less than $0.40  (appropriately  adjusted for any stock splits,  stock
combinations  or similar events  occurring prior to such time) (if the holder of
the Common Stock or Common Stock Equivalent so issued shall at any time, whether
by  operation  of  purchase  price  adjustments,   reset  provisions,   floating
conversion,  exercise  or  exchange  prices or  otherwise,  or due to  warrants,
options or rights  issued in  connection  with such  issuance,  be  entitled  to
receive  shares  of  Common  Stock at a price  less  than  $0.40  (appropriately
adjusted for any stock splits,  stock  combinations or similar events  occurring
prior to such time),  such  issuance  shall be deemed to have  occurred for less
than $0.40  (appropriately  adjusted for any stock splits, stock combinations or
similar events occurring prior to such time)), then, at the option of the Holder
for such exercises as it shall indicate,  the Exercise Price shall be multiplied
by a fraction,  the  numerator  of which shall be the number of shares of Common
Stock  outstanding  immediately  prior to the  issuance of such shares of Common
Stock or such Common Stock Equivalents plus the number of shares of Common Stock
which the  offering  price  for such  shares  of  Common  Stock or Common  Stock
Equivalents  would purchase at the Exercise Price,  and the denominator of which
shall be the sum of the number of shares of Common Stock outstanding immediately
prior to such  issuance  plus the number of shares of Common  Stock so issued or
issuable.  Such  adjustment  shall be made  whenever such Common Stock or Common
Stock Equivalents are issued. The Company shall notify the Holder in writing, no
later than the Trading Day  following the issuance of any Common Stock or Common
Stock  Equivalent  subject to this section,  indicating  therein the  applicable
issuance price, or of applicable reset price,  exchange price,  conversion price
and other pricing terms.  Notwithstanding  the foregoing,  no adjustment will be
made under this Section 9(c) in respect of:

                  (1) any grant of an  option or  warrant  for  Common  Stock or
issuance  of any shares of Common  Stock  upon the  exercise  of any  options or
warrants to employees,  officers and directors of or  consultants to the Company
pursuant to any stock option plan,  employee stock purchase plan or similar plan
or  incentive  or  consulting  arrangement  approved by the  Company's  board of
directors;

                  (2) any  restricted  stock  awards  approved by the  Company's
Board of Directors;

                  (3) shares of Common Stock or Common Stock Equivalents  issued
as consideration for the acquisition of another company or business in which the
shareholders of the Company do not have an ownership interest, which acquisition
has been approved by the Board of Directors of the Company;

                                       6
<PAGE>

                  (4)  any  rights  or  agreements  to  purchase   Common  Stock
Equivalents  outstanding on the date hereof and as specified in Schedule  3.1(g)
to the Purchase  Agreement (but not as to any amendments or other  modifications
to the number of Common Stock issuable thereunder,  the terms set forth therein,
or the exercise price set forth therein);

                  (5)  issuance  of shares of Common  Stock to  Logisticorp  and
Southwest Resource Preservation, Inc., based upon the issuance and conversion of
outstanding convertible  debentures,  with the issuance of said Common Stock not
to exceed 700,000 shares; or

                  (6) up to an  aggregate  of  500,000  shares of  Common  Stock
(including  any shares of Common  Stock  issuable  in  respect  of Common  Stock
Equivalents)  issued or issuable as part of an equipment  financing  line in the
ordinary  course of  business  at a price not less than the market  price of the
Common Stock at the time of the issuance.

                  (ii) If, at any time while this  Warrant is  outstanding,  the
Company or any Subsidiary  issues Common Stock  Equivalents at a price per share
that floats or resets or otherwise  varies or is subject to adjustment  based on
market  prices of the  Common  Stock (a  "FLOATING  PRICE  SECURITY"),  then for
purposes of applying the preceding  paragraph in connection  with any subsequent
exercise, the Exercise Price will be determined separately on each Exercise Date
and will be deemed to equal the  lowest  price per share at which any  holder of
such Floating  Price  Security is entitled to acquire  shares of Common Stock on
such Exercise Date (regardless of whether any such holder actually  acquires any
shares on such date).

            (d) Number of Warrant Shares.  Simultaneously with any adjustment to
the Exercise Price pursuant to this Section 9, the number of Warrant Shares that
may be purchased  upon  exercise of this Warrant shall be increased or decreased
proportionately,  so that after such  adjustment  the aggregate  Exercise  Price
payable hereunder for the adjusted number of Warrant Shares shall be the same as
the aggregate Exercise Price in effect immediately prior to such adjustment.

            (e)  Calculations.  All  calculations  under this Section 9 shall be
made to the nearest cent or the nearest 1/100th of a share,  as applicable.  The
number of shares of Common Stock outstanding at any given time shall not include
shares owned or held by or for the account of the Company,  and the  disposition
of any such shares shall be considered an issue or sale of Common Stock.

            (f) Notice of  Adjustments.  Upon the occurrence of each  adjustment
pursuant to this  Section 9, the Company at its expense  will  promptly  compute
such  adjustment  in  accordance  with the terms of this  Warrant  and prepare a
certificate setting forth such adjustment, including a statement of the adjusted
Exercise Price and adjusted number or type of Warrant Shares or other securities
issuable  upon  exercise  of  this  Warrant  (as  applicable),   describing  the
transactions  giving  rise to such  adjustments  and showing in detail the facts
upon which such  adjustment  is based.  Upon written  request,  the Company will
promptly  deliver  a copy of each  such  certificate  to the  Holder  and to the
Company's Transfer Agent.

                                       7
<PAGE>

            (g)  Notice of  Corporate  Events.  If the  Company  (i)  declares a
dividend or any other  distribution  of cash,  securities  or other  property in
respect of its Common Stock, including without limitation any granting of rights
or warrants to subscribe for or purchase any capital stock of the Company or any
Subsidiary, (ii) authorizes or approves, enters into any agreement contemplating
or  solicits  stockholder  approval  for any  Fundamental  Transaction  or (iii)
authorizes the voluntary  dissolution,  liquidation or winding up of the affairs
of the Company, then the Company shall deliver to the Holder a notice describing
the material  terms and conditions of such  transaction  (but only to the extent
such disclosure would not result in the  dissemination  of material,  non-public
information  to the  Holder) at least 10 calendar  days prior to the  applicable
record or  effective  date on which a Person  would need to hold Common Stock in
order to  participate  in or vote  with  respect  to such  transaction,  and the
Company  will take all steps  reasonably  necessary  in order to insure that the
Holder is given the practical opportunity to exercise this Warrant prior to such
time so as to participate in or vote with respect to such transaction; provided,
however, that the failure to deliver such notice or any defect therein shall not
affect the  validity of the  corporate  action  required to be described in such
notice.

      10.  Payment of Exercise  Price.  The Holder may pay the Exercise Price in
one of the following manners:

            (a) Cash  Exercise.  The Holder may  deliver  immediately  available
funds; or

            (b) Cashless Exercise.  If an Exercise Notice is delivered following
the earlier of the (i) Effectiveness Date or (ii) Effective Date, at a time when
a registration  statement  permitting the Holder to resell the Warrant Shares is
not  then  effective  or the  prospectus  forming  a part  thereof  is not  then
available  to the Holder for the resale of the Warrant  Shares,  then the Holder
may notify the Company in an Exercise Notice of its election to utilize cashless
exercise,  in which  event the  Company  shall issue to the Holder the number of
Warrant Shares determined as follows:

                            X = Y [(A-B)/A]

                           where:

                                    X = the number of Warrant Shares to be
                                    issued to the Holder.

                                    Y  =  the  number  of  Warrant  Shares  with
                                    respect  to  which  this  Warrant  is  being
                                    exercised.

                                    A = the  average of the  closing  prices for
                                    the five Trading Days  immediately  prior to
                                    (but not including) the Exercise Date.

                                    B = the Exercise Price.

For purposes of Rule 144  promulgated  under the Securities Act, it is intended,
understood  and  acknowledged  that the  Warrant  Shares  issued  in a  cashless
exercise  transaction  shall be deemed to have been acquired by the Holder,  and
the holding period for the Warrant Shares shall be deemed to have commenced,  on
the date this Warrant was originally issued.

                                       8
<PAGE>

      11. Limitations on Exercise.

            (a)  Notwithstanding  anything to the contrary contained herein, the
number of Warrant Shares that may be acquired by the Holder upon any exercise of
this  Warrant (or  otherwise in respect  hereof)  shall be limited to the extent
necessary to insure that, following such exercise (or other issuance), the total
number of shares of Common Stock then beneficially  owned by such Holder and its
Affiliates  and any other  Persons  whose  beneficial  ownership of Common Stock
would be  aggregated  with the  Holder's  for  purposes of Section  13(d) of the
Exchange  Act,  does not  exceed  4.999%  of the  total  number  of  issued  and
outstanding  shares of Common  Stock  (including  for such purpose the shares of
Common  Stock  issuable  upon  such  exercise).  For such  purposes,  beneficial
ownership  shall be determined in accordance  with Section 13(d) of the Exchange
Act and the rules and regulations promulgated  thereunder.  This provision shall
not  restrict the number of shares of Common Stock which a Holder may receive or
beneficially  own in  order to  determine  the  amount  of  securities  or other
consideration  that  such  Holder  may  receive  in the  event of a  Fundamental
Transaction as contemplated  in Section 9 of this Warrant.  By written notice to
the Company,  the Holder may waive the provisions of this Section 11(a), but any
such  waiver  will not be  effective  until the 61st day after  delivery of such
notice, nor will any such waiver effect any other Holder.

            (b)  Notwithstanding  anything to the contrary contained herein, the
number of Warrant Shares that may be acquired by the Holder upon any exercise of
this  Warrant (or  otherwise in respect  hereof)  shall be limited to the extent
necessary to insure that, following such exercise (or other issuance), the total
number of shares of Common Stock then beneficially  owned by such Holder and its
Affiliates  and any other  Persons  whose  beneficial  ownership of Common Stock
would be  aggregated  with the  Holder's  for  purposes of Section  13(d) of the
Exchange  Act,  does not  exceed  9.999%  of the  total  number  of  issued  and
outstanding  shares of Common  Stock  (including  for such purpose the shares of
Common  Stock  issuable  upon  such  exercise).  For such  purposes,  beneficial
ownership  shall be determined in accordance  with Section 13(d) of the Exchange
Act and the rules and regulations promulgated  thereunder.  This provision shall
not  restrict the number of shares of Common Stock which a Holder may receive or
beneficially  own in  order to  determine  the  amount  of  securities  or other
consideration  that  such  Holder  may  receive  in the  event of a  Fundamental
Transaction as contemplated in Section 9 of this Warrant.  This  restriction may
not be waived.

      12. No Fractional  Shares.  No fractional shares of Warrant Shares will be
issued  in  connection  with  any  exercise  of  this  Warrant.  In  lieu of any
fractional shares which would, otherwise be issuable, the Company shall pay cash
equal to the product of such  fraction  multiplied  by the closing  price of one
Warrant  Share as  reported  by the  applicable  Trading  Market  on the date of
exercise.

      13.  Notices.  Any and all notices or other  communications  or deliveries
hereunder  (including,  without  limitation,  any Exercise  Notice)  shall be in
writing and shall be deemed given and  effective on the earliest of (i) the date
of  transmission,  if such notice or communication is delivered via facsimile at
the facsimile number specified in this Section prior to 6:30 p.m. (New York City
time)  on  a  Trading  Day,  (ii)  the  next  Trading  Day  after  the  date  of
transmission,  if such notice or communication is delivered via facsimile at the
facsimile number specified in this Section on a day that is not a Trading Day or
later than 6:30 p.m. (New York City time) on any Trading Day,  (iii) the Trading
Day following the date of mailing,  if sent by nationally  recognized  overnight
courier service, or (iv) upon actual receipt by the party to whom such notice is
required to be given. The addresses for such communications  shall be: (i) if to
the Company, to Calypte Biomedical Corporation, Attn: President, or to Facsimile
No.:  (510)  814-8494 (or such other  address as the Company  shall  indicate in
writing in  accordance  with this  Section),  or (ii) if to the  Holder,  to the
address or  facsimile  number  appearing  on the Warrant  Register or such other
address  or  facsimile  number as the  Holder  may  provide  to the  Company  in
accordance with this Section.

                                       9
<PAGE>

      14.  Warrant  Agent.  The Company  shall serve as warrant agent under this
Warrant.  Upon 10 days'  notice to the  Holder,  the  Company  may appoint a new
warrant agent.  Any corporation  into which the Company or any new warrant agent
may be merged or any corporation  resulting from any  consolidation to which the
Company or any new warrant  agent shall be a party or any  corporation  to which
the  Company  or  any  new  warrant  agent  transfers  substantially  all of its
corporate trust or shareholders  services  business shall be a successor warrant
agent under this Warrant  without any further act.  Any such  successor  warrant
agent shall  promptly  cause  notice of its  succession  as warrant  agent to be
mailed (by first class mail, postage prepaid) to the Holder at the Holder's last
address as shown on the Warrant Register.

      15. Miscellaneous.

            (a) This Warrant shall be binding on and inure to the benefit of the
parties  hereto and their  respective  successors  and  assigns.  Subject to the
preceding  sentence,  nothing in this Warrant  shall be construed to give to any
Person  other than the  Company  and the Holder  any legal or  equitable  right,
remedy or cause of action under this  Warrant.  This Warrant may be amended only
in  writing  signed by the  Company  and the  Holder  and their  successors  and
assigns.

            (b) All questions concerning the construction, validity, enforcement
and  interpretation  of this  Warrant  shall be  governed by and  construed  and
enforced in  accordance  with the internal laws of the State of New York (except
for matters governed by corporate law in the State of Delaware),  without regard
to the principles of conflicts of law thereof.  Each party agrees that all legal
proceedings  concerning  the  interpretations,  enforcement  and defense of this
Warrant  and  the  transactions  herein  contemplated  ("PROCEEDINGS")  (whether
brought  against  a party  hereto or its  respective  Affiliates,  employees  or
agents) shall be commenced exclusively in the New York Courts. Each party hereto
hereby irrevocably submits to the exclusive  jurisdiction of the New York Courts
for the adjudication of any dispute hereunder or in connection  herewith or with
any transaction  contemplated hereby or discussed herein, and hereby irrevocably
waives,  and  agrees not to assert in any  Proceeding,  any claim that it is not
personally  subject  to the  jurisdiction  of any New York  Court,  or that such
Proceeding has been commenced in an improper or inconvenient  forum.  Each party
hereto hereby  irrevocably  waives  personal  service of process and consents to
process  being  served in any such  Proceeding  by  mailing a copy  thereof  via
registered or certified  mail or overnight  delivery (with evidence of delivery)
to such party at the address in effect for notices to it under this  Warrant and
agrees that such service shall constitute good and sufficient service of process
and notice thereof. Nothing contained herein shall be deemed to limit in any way
any right to serve  process in any manner  permitted  by law.  Each party hereto
hereby  irrevocably  waives,  to the fullest extent permitted by applicable law,
any and all right to trial by jury in any  legal  proceeding  arising  out of or
relating to this  Warrant or the  transactions  contemplated  hereby.  If either
party shall  commence a Proceeding  to enforce any  provisions  of this Warrant,
then the prevailing  party in such  Proceeding  shall be reimbursed by the other
party for its  attorney's  fees and other costs and expenses  incurred  with the
investigation, preparation and prosecution of such Proceeding.

                                       10
<PAGE>

            (c) The headings herein are for convenience  only, do not constitute
a part of this  Warrant  and shall  not be deemed to limit or affect  any of the
provisions hereof.

            (d) In case any one or more of the  provisions of this Warrant shall
be invalid or unenforceable in any respect,  the validity and  enforceability of
the  remaining  terms and  provisions  of this  Warrant  shall not in any way be
affected or impaired thereby and the parties will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially  reasonable
substitute  therefor,  and upon so agreeing,  shall  incorporate such substitute
provision in this Warrant.

            (e) Prior to exercise of this Warrant,  the Holder hereof shall not,
by reason of by being a Holder,  be entitled to any rights of a stockholder with
respect to the Warrant Shares

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK,
                             SIGNATURE PAGE FOLLOWS]

                                       11
<PAGE>

      IN  WITNESS  WHEREOF,  the  Company  has  caused  this  Warrant to be duly
executed by its authorized officer as of the date first indicated above.

                                    CALYPTE BIOMEDICAL CORPORATION

                                    By:________________________________
                                       Name:
                                       Title:

                                       12
<PAGE>

                                 EXERCISE NOTICE

                         CALYPTE BIOMEDICAL CORPORATION

                           WARRANT DATED JULY 9, 2004

The  undersigned  Holder  hereby  irrevocably  elects to purchase  _____________
shares of Common Stock  pursuant to the above  referenced  Warrant.  Capitalized
terms used herein and not  otherwise  defined have the  respective  meanings set
forth in the Warrant.

(1)   The   undersigned   Holder   hereby   exercises   its  right  to  purchase
      _________________ Warrant Shares pursuant to the Warrant.

(2)   The Holder  intends that  payment of the  Exercise  Price shall be made as
      (check one):

                      ____"Cash Exercise" under Section 10

                    ____"Cashless Exercise" under Section 10

(3)   If the holder has elected a Cash Exercise, the holder shall pay the sum of
      $____________ to the Company in accordance with the terms of the Warrant.

(4)   Pursuant to this Exercise Notice,  the Company shall deliver to the holder
      _______________  Warrant  Shares  in  accordance  with  the  terms  of the
      Warrant.

(5)   By its delivery of this Exercise  Notice,  the undersigned  represents and
      warrants to the Company that in giving  effect to the  exercise  evidenced
      hereby the  Holder  will not  beneficially  own in excess of the number of
      shares of Common Stock (determined in accordance with Section 13(d) of the
      Securities Exchange Act of 1934) permitted to be owned under Section 11 of
      this Warrant to which this notice relates.

Dated:___________________,____      Name of Holder:

                                    (Print)_______________________________

                                    By:___________________________________
                                        Name:_____________________________
                                        Title:____________________________

                                    (Signature  must conform in all respects
                                    to name of  holder as  specified  on the
                                    face of the Warrant)

                                       13

<PAGE>

                           Warrant Shares Exercise Log

<TABLE>
<CAPTION>
-------------------- ----------------------------- ---------------------------------- ---------------------
                     Number of Warrant Shares      Number of Warrant Shares           Number of Warrant
Date                 Available to be Exercised     Exercised                          Shares Remaining to
                                                                                      be Exercised
-------------------- ----------------------------- ---------------------------------- ---------------------
<S>                  <C>                           <C>                                <C>

-------------------- ----------------------------- ---------------------------------- ---------------------
</TABLE>

                                       14
<PAGE>

                         CALYPTE BIOMEDICAL CORPORATION

                     WARRANT ORIGINALLY ISSUED JULY 9, 2004

                                 WARRANT NO. [ ]

                               FORM OF ASSIGNMENT

         [To be completed and signed only upon transfer of Warrant]

         FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers
unto    ________________________________    the   right   represented   by   the
above-captioned Warrant to purchase ____________ shares of Common Stock to which
such Warrant  relates and appoints  ________________  attorney to transfer  said
right on the  books of the  Company  with  full  power  of  substitution  in the
premises.

Dated:   _______________, ____

                                    _______________________________________
                                    (Signature  must  conform in all respects
                                    to name of holder as specified on the face
                                    of the Warrant)

                                    _______________________________________
                                    Address of Transferee

                                    _______________________________________

                                    _______________________________________

In the presence of:

_________________________________

                                       15Unassociated Document

EXHIBIT 10.27

CONFIDENTIAL TREATMENT REQUESTED

DEVELOPMENT AGREEMENT

THIS DEVELOPMENT AGREEMENT (“Agreement”) is made this 8th day of June, 2004, by and between Mobilepro Corp., a Delaware corporation, and NeoReach, Inc., a Delaware corporation, each having its principal office at 6701 Democracy Blvd, Suite 300, Bethesda, Maryland 20817, USA, (collectively, “Mobilepro”), on the one hand, and Information and Communications University, a university organized and existing under the laws of the Republic of Korea, having its principal place of business at 119, Mujiro Yuseong-gu, Dae-jeon the Republic of Korea (“ICU”).

 

WITNESSETH:

WHEREAS, Mobilepro and ICU wish to enter into a Development Agreement, regarding the development of a ZigBee RF transceiver chip (the “ZigBee Chip”); and

WHEREAS, ICU has the expertise and facilities to undertake such Development (as defined below) and is willing to undertake such services.

NOW, THEREFORE, this Agreement is hereby entered by and between the parties for the purpose of memorializing the terms and conditions by which Mobilepro intends to engage ICU for its performance of Development and other services related to the ZigBee Chip. In consideration of the promises and covenants herein contained, the parties hereto agree as follows:

1.  Definitions

1.1    “Know-How” shall mean know-how and show-how, electrical and mechanical designs and drawings, logic diagrams, electronic schematics, wiring diagrams, layouts, mask works, methods of implementation, architectures, functionalities, test data, operating parameters, product in object code or source code form, prototypes, production models, hardware and software products and documentation.

1.2    “Intellectual Property Rights” or “IPs” shall mean all Patent Rights, formal and informal, including but not limited to registrations, applications, renewals and extensions therefore, copyrights (including, but not limited to, ownership rights in any designs, blue prints, schematics, software, electronic circuitry, computer code, audio-visual effects, and methods of operation, moral rights and any related documentation), mask work rights, including without limitation, all applications and registrations with respect thereto, rights in trade secrets, Know-How, trademarks and trade name and all other intellectual property rights recognized by U.S. laws and/ or applicable foreign and international laws, treaties and conventions.

1.3    “Party” shall mean Mobilepro or ICU or, when used in the plural, Mobilepro and ICU.

 

	

 

	 

1.4    "Patent Rights” means all patents and patent applications (which for all purposes of this Agreement shall be deemed to include certificates of invention and applications for certificates of invention) throughout the world, including any substitutions, extensions, reissues, renewals, divisions or continuations.

1.5    “Working Prototype” means all development and testing completed to provide a ZigBee Chip in package form meeting all specifications described in Appendix I.

1.6    “Person” shall mean an individual, a partnership, a joint venture, a corporation, a trust, an estate, an unincorporated organization, or any entity, or a government, or any department or agency.

1.7    “Technical Maintenance” means that ICU will respond to questions and provide reasonable assistance, during the Development Agreement period, concerning the technical aspects and operation of the ZigBee Chip via telephone or other medium and will correct any defects or deficiencies in the ZigBee Chip that cause it not to conform to the specifications described in Appendix I and perform any adjustments requested by Mobilepro.

 

1.8    “Developed Technology” means the materials and IPs provided, created or developed by ICU in connection with the Development under this Agreement.

2.  Development Services

2.1    Development as defined in this Agreement shall be the development of the ZigBee Chip Working Prototype. ICU may help but not responsible for the commercialization of the Working Prototype.

2.2    Mobilepro and ICU shall abide by the terms and conditions of this Agreement.

2.3    All modifications and/or amendments to the above definition of Development shall be mutually agreed upon by and between Mobilepro and ICU.

2.4    Mobilepro and ICU shall abide by the timetable set forth in the Requirements and Development Schedule for Mobilepro ZigBee Chip attached hereto as Appendix I unless modified by a pertinent section of this Agreement.

 

2.5    ICU represents and warrants that the developed technology deliverables set forth in Appendix I will function in all material respects in accordance with the specifications relating thereto in Appendix I.

 

2.6    ICU may not use any personnel other than its employees, including independent contractors or subcontractors (collectively “Contractors”), to work on the Development without the written permission of Mobilepro which permission shall not be unreasonably withheld or delayed. Before any permitted Contractor begins work or is provided access to Confidential Information, ICU shall cause each such Contractor: (a) to agree in writing to maintain the confidentiality of Confidential Information, in terms substantially similar to the terms applicable to ICU set forth in this Agreement; (b) to agree not to hire any sub-subcontractor to carry out its duties; and (c) to assign to Mobilepro any rights in work product relating to the Development developed by Contractor in accordance with Section 11.

 

	

 

	 

 

3.  Development Procedures

3.1    Both parties shall abide by the Development Procedures and Schedule specified in the Requirements and Development Schedule for Mobilepro ZigBee Chip attached hereto as Appendix I. The ZigBee Chip will be developed in [*] stages [*] as set forth in Appendix I.

3.2    Transfer of Technical Materials

a.   Project Team. Mobilepro and ICU shall form the Project Transfer Team, which shall be responsible for the development of the products and related technical materials from ICU.

 

b.   Transfer of Technical Documents. ICU shall provide Mobilepro with technical reports generated at each development Stage until the completion of the ZigBee Chip, in each case within 20 days of completion of such Stage.

 

3.3    “Acceptance” of Stage [*], as applicable, will occur when the deliverables specified in Appendix I for such Stage meet applicable specifications described in Appendix I to the extent of Mobilepro’s reasonable acceptance level.

4.  Term 

This Agreement shall become effective on the date set forth in the preamble and, unless earlier terminated pursuant to Section 12 below, remain in effect until the Acceptance by Mobilepro of the Stage [*] Working Prototype of the ZigBee Chip. A Requirements and Development Schedule for Mobilepro ZigBee Chip is described in Appendix I. Mobilepro and ICU shall observe said schedule during the completion of the various steps of Development.

5.  Duties of ICU

5.1    ICU shall perform the Development as defined herein. At completion of the Working Prototype of the ZigBee Chip, ICU shall transfer and provide Mobilepro with the ZigBee Chip, all documentation supporting the ZigBee Chip, all IP papers, and all other items as agreed between the parties.

5.2    During the term of this Agreement, Mobilepro may request a modification of the properties and specifications of the ZigBee Chip, and upon a written approval by ICU thereof, ICU shall use best efforts to implement said modifications to the Development.

5.3    ICU will provide Technical Maintenance of the ZigBee Chip during the Development.

 

	

* Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and filed separately with the Securities and Exchange Commission.

	 

5.4    Each Party hereby warrants that it (a) is capable of performing and has full legal power to perform this Agreement, and (b) to its knowledge such performance will not result in any violation of any relevant laws or breach of any agreement to which such Party is a party.

5.5    ICU warrants that it owns the technical information necessary to successfully complete the Development.

5.6    Each Party warrants and acknowledges that time is of the essence.

6.  Support from Mobilepro

 

6.1    Mobilepro shall provide ICU all such information and a senior engineer that is reasonably necessary for ICU to perform its duties under this Agreement.

7.  Payment

7.1    The payment under this Agreement to be paid by Mobilepro to ICU in exchange for the completion of development of the Zigbee Chip Working Prototype as specified herein by ICU is US $[*] (the “Development Fee”). 

7.2    The Development Fee shall be paid according to the following schedule: 

a.   An initial payment of US $

b.   business days of Acceptance by Mobilepro of [*] (as described in Section 3.1 above); 

c.   A final payment of US $

7.3    All fees payable to any Party under this Agreement shall be paid to such Party at its address set forth herein without set-off or counter-claim, and without any deduction or withholding for or on account of any present or future taxes, imposts or fees (“Taxes”) imposed, levied or assessed by the country of domicile of the paying Party or any political subdivision or taxing authority thereof, or any other jurisdiction from or through which payments may be made. Each Party shall indemnify and hold the other Party harmless from and against all Taxes, penalties and interest (direct or indirect) arising from this Agreement in the country of domicile of the paying Party and any other country other than the country of domicile of the Party receiving payments hereunder. 

8.  Manufacturing and Distributing 

8.1    Upon request from Mobilepro, ICU will provide technical support of the ZigBee Chip, which at ICU’s option could or could not involve re-fabrication of the chip, for a period of [*] following the completion and Acceptance of [*] (as described herein) at no additional cost to Mobilepro.

 

	

* Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and filed separately with the Securities and Exchange Commission.

	 

 

9.  Confidentiality

9.1    In connection with this Agreement, each Party will furnish to the other certain information that is either non-public, confidential or propriety in nature (the “Confidential Information”). For purposes of this Agreement, the term “Confidential Information” shall include all information (including information furnished before the execution of this Agreement) furnished to either Party, its employees, agents, or representatives, including, without limitation, experts and other consultants (collectively, the “Representatives”) including, without limitation, all information provided by either Party pursuant to Section 3 above, and all reports, analyses, compilations, data, studies or other documents prepared by a Party or its Representatives containing or
based, in whole or in part, on any such Confidential Information. “Confidential Information” shall also include the terms of this Agreement. 

9.2    The Confidential Information will be kept confidential for so long as it shall fall within the definition of Confidential Information herein, and will not, without the prior written consent of the relevant Party, be disclosed by the other Party or its Representatives, in any manner, in whole or in part, and the Confidential Information will not be used by either Party or its Representatives, directly or indirectly, for any purpose other than the transactions contemplated by this Agreement. Each Party agrees (a) that its Representatives will be informed of the confidential nature of the Confidential Information and the requirement that it not be used other than for the purposes permitted herein, and will agree to protect the Confidential Information (in the case of Contractors such

agreement shall be in writing as provided in Section 2.5), and (b) in any event, the receiving Party will be responsible for any disclosure of Confidential Information, or any other breach of this Agreement, by any of its Representatives.

9.3    Mobilepro will be permitted to issue, at its own discretion, public press releases relating to the following occurrences; 1) upon signing of this Agreement Mobilepro may announce that is has entered into an Agreement with a major university (name not to be disclosed) and disclose the broad scope of the Agreement, 2) upon meeting key milestones of the agreement (i.e. completion of phases, additional patent applications, completion of development project, etc.) Mobilepro may announce each accomplishment, 3) filing of patent applications resulting from development of the ZigBee Chip, 4) and other significant items that would be of material interest to its shareholder base.

9.4    All documents or other materials furnished by either Party and constituting Confidential Information, and all copies of such Confidential Information, will be destroyed or promptly returned upon request except to the extent that the receiving party retains an ownership right in, or license right to use, such Confidential Information as provided herein. 

9.5    The term “Confidential Information” shall exclude any materials that: (a) become generally available to the public other than as a result of disclosure by the receiving Party; (b) become available to a Party on a non-confidential basis and not in contravention of applicable law from a source (other than the other Party or its Representatives) that is not bound by a confidential relationship concerning such Confidential Information; or (c) was known to the other Party or its Representatives on a non-confidential basis and not in contravention of applicable law prior to the execution of this Agreement.

 

	

 

	 

9.6    If either Party or any individual or entity to whom such Party has transmitted Confidential Information are requested or become legally compelled (by oral questions, interrogatories, request for information or documents, subpoena, civil investigative demands or similar process) to disclose any of the Confidential Information, such Party will provide the other with prompt written notice. If a protective order or other remedy is not obtained, then only that part of the Confidential Information that is legally required to be furnished will be provided.

10.  Intellectual Property, Patent and Trademark

10.1     ICU Warranty. ICU shall not knowingly, intentionally or negligently breach any Intellectual Property Rights of any third parties, and ICU represents that to its actual knowledge, without investigation, the technical information or technology it actually owns (the “ICU Technology”) does not infringe upon any third party’s Intellectual Property Rights and that it has no actual knowledge, without investigation, nor has it been notified by a third party of a possibility that such ICU Technology may infringe upon any Intellectual Property Rights. ICU further represents that there are no pending claims or lawsuits concerning the ICU Technology.

10.2     Mobilepro Warranty. Mobilepro shall not knowingly, intentionally or negligently breach any Intellectual Property Rights of any third parties, and Mobilepro represents that to its actual knowledge, without investigation, the technical information or technology it actually owns other than the Developed Technology (the “Mobilepro Technology”) does not infringe upon any third party’s Intellectual Property Rights and that it has no actual knowledge, without investigation, nor has it been notified by a third party of a possibility that such Mobilepro Technology may infringe upon any Intellectual Property Rights. Mobilepro further represents that there are no pending claims or lawsuits concerning the Mobilepro Technology.

10.3     Indemnification of Mobilepro by ICU. ICU shall defend and hold Mobilepro harmless from any claim of any third party that the normal use or operation of ICU Technology or Developed Technology infringes any Intellectual Property Rights, provided that ICU is given immediate and full control of such claim and that Mobilepro does not prejudice ICU defense of such claim and provides all reasonable assistance to ICU for such defense. ICU shall be entitled to compromise or settle any such claims without the consent of Mobilepro to the extent such suits may be compromised or settled without prejudice to any rights or interests of Mobilepro. Mobilepro may be represented by and actively participate through its own counsel in any suit or
proceeding described in this Section 10.3 at its own expense.

 

10.4     Indemnification of ICU by Mobilepro. Mobilepro shall defend and hold ICU harmless from any claim of any third party that the normal use or operation of Mobilepro Technology infringes any Intellectual Property Rights, provided that Mobilepro is given immediate and full control of such claim and that ICU does not prejudice Mobilepro’s defense of such claim and provides all reasonable assistance to Mobilepro for such defense. Mobilepro shall be entitled to compromise or settle any such claims without the consent of ICU to the extent such suits may be compromised or settled without prejudice to any rights or interests of ICU. ICU may be represented by and actively participate through its own counsel in any suit or proceeding
described in this Section 10.4 at its own expense. This indemnification obligation shall not negate, abridge, or otherwise reduce any other right or obligation of indemnity or contribution which exists in favor of the Mobilepro under Section 10.3.

 

	

 

	 

 

11.  Proprietary Rights

11.1     Mobilepro Ownership of Prior IP. The parties agree that Mobilepro shall solely own all rights, title and interest in IPs that are developed by Mobilepro or provided by Mobilepro to ICU in the development of the ZigBee Chip Module. Nothing in this Agreement is intended to affect or restrict Mobilepro’s rights in any IPs that are provided by Mobilepro.

11.2     ICU Ownership of Prior IP. The parties agree that ICU shall solely own all rights, title and interest in IPs that were owned by ICU previous to the Development of the ZigBee Chip (“ICU Prior IP”), provided that any such IP that is included or incorporated in the Working Prototype or other Developed Technology shall be owned by Mobilepro as part of the Developed Technology pursuant to Section 

 

11.3     Ownership of Developed IP. The title and rights to any Developed Technology, including any patent application covering the ZigBee Chip, or any patent(s) maturing from such a patent application, will be owned by Mobilepro as of the time created. To the greatest extent permitted under law, the Developed Technology shall be considered a work-for-hire made pursuant to a written instrument. ICU will cooperate to execute and record documents, including an Assignment Document included in Appendix I, reflecting the appropriate ownership of the Developed Technology as described in this Section 11.3 in all countries where rights are or may be claimed.

 

11.4     Derivative Works and Further Assurances. Mobilepro shall individually own all Intellectual Property Rights associated with any derivative work(s) created in connection with the Development and this Agreement. ICU agrees, during and after the term of this Agreement during the warranty period, at Mobilepro’s request and expense, to provide reasonable assistance and cooperation to Mobilepro and its designees, and to give testimony and execute documents, and to take such further acts reasonably requested by Mobilepro to acquire, transfer, maintain, perfect, and enforce Mobilepro’s Intellectual Property Rights in the Developed Technology and derivative works as described
herein. Each Party hereby appoints the officers of the other Party as its attorney-in-fact to execute documents on behalf of it and its heirs, successors and assigns for this limited purpose; said appointment as attorney-in-fact is coupled with an interest. Further, ICU covenants and agrees not to reverse engineer or otherwise seek to recreate the work done for Mobilepro pursuant to this Agreement.

 

 

	

 

	 

 

11.5     Patents. For any Developed Technology, MobilePro may seek patent protection in any country at its own expense and with counsel of its choosing. Existing and future patent applications will be at Mobilepro’s option and expense. ICU will provide assistance in connection with such patent prosecution in accordance with Section 11.4.

12.  Termination; Survival

12.1     Termination. 

a.   This Agreement may be terminated by either non-breaching party in the event of a breach of any material provision of this Agreement by one of the parties, with two (2) weeks prior written notice regarding the breach to the breaching party, and such notice shall offer a period of two (2) weeks during which to cure the breach. If said breach is not cured during said two (2) weeks, this Agreement shall be deemed terminated as of the end of the two (2) week period. 

b.   This Agreement may be terminated by: 

(1)  Mobilepro, upon written notice to ICU, in the event of any delay of more than one (1) month of the Development as set forth in the Requirements and Development Schedule for Mobilepro ZigBee RF Transceiver Chip set forth in Appendix I, or Mobilepro’s assessment of the inability of ICU to continue the Development, and

 

(2)  ICU, upon written notice to Mobilepro, in the event of any delay of more than one (1) month that the inability to complete the Development according to the Requirements and Development Schedule for Mobilepro ZigBee RF Transceiver Chip set forth in Appendix I is caused by Mobilepro or if Mobilepro fails to make the payments described in Section 7.2 and fails to cure such payment default upon 30 days prior written notice. 

 

c.    Notwithstanding anything to the contrary in the provision in this Section 12.1, this Agreement shall immediately terminate at the occurrence of one of the following: 

(1)  Any party to this Agreement files for voluntary or involuntary Bankruptcy; 

 

(2)  Any party to this Agreement is subject to foreclosure actions by a governmental entity as a result of non-payment of taxes; 

 

(3)  Any party to this Agreement assigns to a third party without the prior written consent of the other party the rights and duties under this Agreement, provided, however, that should Mobilepro be acquired by another company, such change of control or assignment by operation of law shall not be deemed an “assignment” for purposes of this Agreement and therefore shall be permissible; or

 

(4)  Any party receives an order to cease business operations from the relevant governmental entities.

 

	

 

	 

 

12.2     Survival of Certain Sections of Agreement Following Termination. Notwithstanding the termination of this Agreement pursuant to Section 12.1 above, each of Section 7 (Payment) (only with respect to amounts earned prior to termination), Section 9 (Confidentiality), Section 10 (Intellectual Property), and Section 11 (Proprietary Rights) shall remain in full force and effect after any such termination.

       

13.  Miscellaneous Provisions

13.1     Independent Advice. The parties have read the foregoing Agreement, have had the benefit its own legal counsel regarding this Agreement, or an opportunity to so obtain said benefit, and hereby warrant, represent, and agree that they understand all of the terms of this Agreement and that they are voluntarily executing the same of its own free will.

13.2     Parties Bear Own Expenses. Each party shall each bear its own expenses incurred in negotiating, preparing and signing this Agreement. 

13.3     Further Assurances. The parties shall perform any further acts and execute and deliver any documents that may be reasonably necessary to carry out the intent of this Agreement.

13.4     Entire Agreement. The understandings set forth herein represent the entire agreement of the Parties with respect to the matters contained herein. The Agreement may not be altered or modified except by mutual agreement of the parties, evidenced in writing and executed by both parties and specifically identified as an amendment to this Agreement. 

13.5     Arbitration. Each party agrees that, unless otherwise required in order to comply with deadlines under the law, it will not file action or institute legal proceedings with respect to any dispute, controversy, or claim arising out of, relating to, or in connection with this Agreement, until it has given the other party written notice of its grievance; the other party has failed to provide a prompt and effective remedy; it has requested that senior executives for both parties to meet and discuss the matter in order to consider informal and amicable means of resolution; and either such meeting failed to occur within thirty (30) days after such request or the meeting did not produce a mutually satisfactory resolution of the matter in such time.

13.6     Attorney's Fees. Should any dispute arise pertaining to this Agreement, the prevailing party in any litigation or arbitration shall be entitled, among other things, to recover reasonable attorneys’ fees and costs incurred in connection with such dispute.

13.7     Integration. This Agreement constitutes the final, complete and exclusive agreement and understanding between and among the parties to it, and supersedes all prior or contemporaneous written or oral agreements.

 

	

 

	 

13.8     Severability. If a provision of this Agreement is held to be illegal or invalid by a court of competent jurisdiction, such provision shall be rewritten by the court to be legal and valid as long as the rewritten provision remains consistent with the intent of the Parties expressed herein or deemed to be severed and deleted. Neither such revision nor such severance and deletion shall affect the validity of the remaining provisions.

13.9     Successors and Assigns. This Agreement shall apply to, bind and inure to the benefit of the Parties and their permitted successors and assigns.

13.10   Counterparts. This Agreement may be executed in one or more counterparts, all of which together shall constitute one and the same Agreement. 

13.11   Interpretation. Parties have each agreed to the use of the particular language of the provisions of this Agreement, and any question of doubtful interpretation shall not be resolved by any rule of interpretation providing for interpretation against a party who causes an uncertainty to exist or against the draft herein.

13.12   Headings. The captions to the several Paragraphs hereof are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Paragraphs hereof.

13.13   Pronouns. Plural shall be substituted for the singular form and/or vice versa, in any place or places herein in which the content requires such substitution(s).

13.14   No Oral Modifications. This Agreement may be amended or modified in writing only, signed by the parties to be charged or bound by such amendment or modifications.

13.15   Waiver. The waiver by either party hereto of any right hereunder or the failure to perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise.

13.16   Notices. Any notice given hereunder to any party shall be given by facsimile, mail (registered or certified, postage prepaid, return receipt requested) or pre-paid private delivery service, as follows:

If to:   MobileproCorp.

       6701 Democracy Blvd, Suite 300

       Bethesda, Maryland 20817, USA

       Fax: (301) 315-9027

If to:   Information and Communications University

 119, Mujiro, Yuseong-gu

 Dae-jeon, Korea

 Fax: 01182428666227

13.17   Applicable Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Maryland without regards to its choice of law provision and any applicable laws of the United States. 

	

 

	 

IN WITNESS WHEREOF, the Parties have executed this Agreement on the date first above mentioned.

 

	 Mobilepro Corp.	 	 	 Information and Communications University
	 	 	 	 
	/s/ 	 	 	/s/ 
	

	 	 	

	Name: Jay O. Wright
Title:    President and CEO	 	 	Name:
Title:
	 	 	 	 
	 	 	 	 /s/ 
	 	 	 	

	 	 	 	Name:
Title:

 

 

	

 

	 

Assignment of Intellectual Property

 

ATTACHMENT 1

Requirements and Development Schedule for Transceiver Chip

ATTACHMENT 2 

Intellectual Property Assignment 

	
 

	 

 

Assignment of Intellectual Property

 

ATTACHMENT 1

	
Requirements and Development Schedule for Mobilepro ZigBee
Chip RF Transceiver Chipset

 

June 1, 2004

Mobilepro

	

 

	 

Assignment of Intellectual Property

1.  Objective

[*]

(1)                    Application Area

- Wireless home, commercial, and industrial security

- Remote thermostats for HVAC systems

- Remote lighting, drape controller

- Universal remote controller to TV, stereo and radio

- Wireless keyboard, mouse and game pads

- Medical monitoring systems

- Industrial and commercial building automation and control

B.  Specifications and requirements for Mobilepro ZigBee 

[*]

 

	

* Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and filed separately with the Securities and Exchange Commission.

	 

 

Assignment of Intellectual Property

 

Chip Characteristics

	
Items
	
Specifications
	
Remarks

	
[*]
	
[*]
	
[*]

	

* Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and filed separately with the Securities and Exchange Commission.

	 

 

Assignment of Intellectual Property

 

Block Diagram (tentative)

[*]

2.  Deliverable Items

[*]

 

	

* Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and filed separately with the Securities and Exchange Commission.

	 

 

Assignment of Intellectual Property

 

3.  Development Schedule

[*]

	

* Confidential treatment has been requested for certain portions of this document pursuant to an application for confidential treatment sent to the Securities and Exchange Commission. Such portions are omitted from this filing and filed separately with the Securities and Exchange Commission.

	 

 

Assignment of Intellectual Property

 

ATTACHMENT 2

ASSIGNMENT OF INTELLECTUAL PROPERTY

WHEREAS, Mobilepro Corp., a Delaware corporation (hereinafter “Mobilepro”), having its principal office at 6701 Democracy Blvd, Suite 300, Bethesda, Maryland 20817, USA, Neoreach, Inc., a Delaware corporation and Mobilepro’s subsidiary (hereinafter “Neoreach”), and Information and Communications University organized and existing under the laws of the Republic of Korea (hereinafter “ICU”), having its principal place of business at 119, Mujiro Yuseong-gu, Dae-jeon the Republic of Korea have entered into a Contract Agreement dated as of June, 1st, 2004 (the "Agreement"); and

 

WHEREAS, ICU agreed in the Agreement to develop certain technology relating to a ZigBee RF Transceiver Chip;

 

WHEREAS, under the Agreement ICU agreed that Mobilepro shall have full ownership of all products of the development services performed pursuant to the Agreement, including any and all patent, copyright, trademark, trade secret, and other property interests relating to such products; and

 

WHEREAS, in performing the development services, ICU has created or acquired an interest in the following intellectual property assets that are to be transferred to Mobilepro (collectively the “Intellectual Property”):

 

[·  The trademark and service mark registrations and applications therefor listed in Schedule A hereto]

 

[·  The ideas, inventions, patents and utility models and applications therefor listed in Schedule A hereto, including all reissues, divisions, continuations, continuations-in-parts, extensions, and  reexaminations thereof or thereon]

 

[·  The copyrights and registrations therefor listed in Schedule A hereto, and all renewals thereof or thereon]

 

WHEREAS, Mobilepro is desirous of acquiring all right, title and interest in and to all Intellectual Property, and ICU has promised, in the Agreement, to cause the same to be assigned; and

 

NOW, THEREFORE, for valuable consideration, including the consideration set forth in the Agreement and other valuable and legally sufficient consideration acknowledged by ICU to have been received in full:

 

1.   ICU does hereby sell, convey, assign and transfer to Mobilepro the entire right, title and interest in, to and under all Intellectual Property, together with the goodwill of the business symbolized by such Intellectual Property, together with all rights and privileges granted and secured thereby, including the full right to sue for past, present or future infringement of such Intellectual Property, these rights to be held and enjoyed by Mobilepro as fully and entirely as the same would have been held and enjoyed by said ICU if this Assignment and sale had not been made.

 

	

             

            

	 

 

Assignment of Intellectual Property

 

2.   ICU hereby covenants that it has full right to convey the entire interest herein assigned and agrees to execute any and all documents reasonably required to effect this Assignment.

 

3.   ICU hereby covenants and agrees that it will cooperate with Mobilepro to enable Mobilepro to enjoy, to the fullest extent, the right, title and interest herein conveyed. ICU's cooperation shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance relating to the Intellectual Property, all to the extent deemed necessary or desirable by Mobilepro for (a) the continued prosecution, if any, of the Intellectual Property, including any interference which may arise, and the making and prosecution of any other foreign or United States application that Mobilepro may elect to pursue stemming from the Intellectual Property, including any divisions, continuations, continuation-in-parts,
substitutions or reissues, and including any interference which may arise during same; (b) participation in any legal or administrative proceedings involving the Intellectual Property, provided, however, that the expense incurred by ICU in providing such cooperation shall be paid for by Mobilepro; and (c) otherwise fully carrying out the terms of this Assignment.

 

4.   The terms and covenants of this Assignment shall inure to the benefit of Mobilepro, its successors and assigns and other legal representatives, and shall be binding upon ICU, its respective heirs, legal representatives and assigns.

 

5.   ICU hereby warrants and represents that it has not entered and will not enter into any assignment, contract, or understanding in conflict herewith.

 

6.   ICU hereby requests that the appropriate patent, trademark or other government offices record this Assignment and issue a new certificate of registration in Mobilepro’s name.

 

IN TESTIMONY WHEREOF, ICU has executed this Assignment this 1st day of June, 2004.

Information and Telecommunications University

 

 

	 	 Information and Telecommunications University
	 	 	 
	 	 	 
	 	 By:	 
	 	 	

	 	 Its:	 
	 	 	

 

	 STATE OF	
 )

	 	
 ) SS:

	 COUNTY OF	
 )

	

 

	 

Assignment of Intellectual Property

 

On this day of , ______, before me appeared ____________________, who, being by me duly sworn, did say that he/she is the ____________________ of Information and Telecommunications University, organized and existing under the laws of the Republic of Korea, and personally known to me to be the same person whose name is subscribed to the foregoing ASSIGNMENT OF INTELLECTUAL PROPERTY (“Assignment”), and acknowledged to me that he/she signed and delivered the foregoing Assignment on behalf of and pursuant to authority from such corporation and that the foregoing Assignment was a free and voluntary act and deed.

 

	 	

Notary Public
	 	
	 	My commission expires:	 
	 	 	

	

 

	 

 

Assignment of Intellectual Property

SCHEDULE A

( ___ Pages)

·   Patents and Patent Applications

           [Specify]

·   Copyrights and Copyright Registrations

           [Specify]

·   Trademarks, Trademark Registrations and Applications

           [Specify]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00068-of-00352.parquet"}]]